Review



quantigene singleplex assay kit  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher quantigene singleplex assay kit
    Quantigene Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantigene singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    quantigene singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    90
    Thermo Fisher quantigene singleplex assay kit
    Quantigene Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantigene singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    quantigene singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher ™quantigene™ singleplex assay kit
    Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene <t>Singleplex</t> assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM
    ™Quantigene™ Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/™quantigene™ singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    ™quantigene™ singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher proteinase k solution quantigene tm singleplex assay kit
    Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene <t>Singleplex</t> assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM
    Proteinase K Solution Quantigene Tm Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinase k solution quantigene tm singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    proteinase k solution quantigene tm singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher quantigene tm singleplex assay kit
    Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene <t>Singleplex</t> assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM
    Quantigene Tm Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantigene tm singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    quantigene tm singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher plate-based qualitative branched dna assay quantigene singleplex assay kit
    Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene <t>Singleplex</t> assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM
    Plate Based Qualitative Branched Dna Assay Quantigene Singleplex Assay Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plate-based qualitative branched dna assay quantigene singleplex assay kit/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    plate-based qualitative branched dna assay quantigene singleplex assay kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene Singleplex assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: Jurkat cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled serially from siRNA-treated cells on the days indicated on the x-axis (A-C). The sampled cells were lysed and frozen. All samples were subjected to QuantiGene Singleplex assays simultaneously for mRNA quantification. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Comparison

    Jurkat cells underwent repeated treatments with siRNAs targeting WAPAL at concentrations of either 1 µM (A) or 2 µM (B), up to a maximum of three doses, administered 3 days apart. Cells were harvested from the siRNA-treated cultures on the days indicated on the x-axis, then lysed and frozen. All samples were analyzed simultaneously for mRNA quantity using the QuantiGene Singleplex assay. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: Jurkat cells underwent repeated treatments with siRNAs targeting WAPAL at concentrations of either 1 µM (A) or 2 µM (B), up to a maximum of three doses, administered 3 days apart. Cells were harvested from the siRNA-treated cultures on the days indicated on the x-axis, then lysed and frozen. All samples were analyzed simultaneously for mRNA quantity using the QuantiGene Singleplex assay. Data points at different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Singleplex Assay, Comparison

    HeLa cells were exposed to siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations shown below the x-axis. Cells were either collected 6 days after treatment (D-F) or sampled periodically from siRNA-treated cells on the days indicated on the x-axis (A-C). The collected cells were lysed and frozen. All samples underwent simultaneous mRNA quantification using QuantiGene Singleplex assays. IC50 values were calculated using the log (inhibitor) – three parameters function in GraphPad Prism. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-9, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: HeLa cells were exposed to siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations shown below the x-axis. Cells were either collected 6 days after treatment (D-F) or sampled periodically from siRNA-treated cells on the days indicated on the x-axis (A-C). The collected cells were lysed and frozen. All samples underwent simultaneous mRNA quantification using QuantiGene Singleplex assays. IC50 values were calculated using the log (inhibitor) – three parameters function in GraphPad Prism. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-9, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Comparison

    Primary human T cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled at intervals from siRNA-treated cells on the days indicated on the x-axis (A-C). The harvested cells were lysed and frozen. All samples were simultaneously analyzed for mRNA levels using QuantiGene Singleplex assays. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points from different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: Primary human T cells were treated with siRNAs targeting WAPAL (A and D), AURKA (B and E), or JAK1 (C and F) at the concentrations indicated below the x-axis. Cells were either harvested 6 days post-treatment (D-F) or sampled at intervals from siRNA-treated cells on the days indicated on the x-axis (A-C). The harvested cells were lysed and frozen. All samples were simultaneously analyzed for mRNA levels using QuantiGene Singleplex assays. IC50 values were determined using the log (inhibitor) – three parameters function in GraphPad Prism. Data points from different time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-7, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Comparison

    Jurkat cells were treated with siRNAs that were either simply phosphorylated or stabilized with 5’-VP at the 5’ end of the antisense strand. The siRNAs targeted WAPAL (A and C) or AURKA (B and D) at concentrations of 2 µM (A-B) or 4 µM (C-D). Samples were periodically collected from the treated cultures as indicated on the x-axis. These samples were frozen and later thawed simultaneously for mRNA quantification using QuantiGene Singleplex assays. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. N=3, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: Jurkat cells were treated with siRNAs that were either simply phosphorylated or stabilized with 5’-VP at the 5’ end of the antisense strand. The siRNAs targeted WAPAL (A and C) or AURKA (B and D) at concentrations of 2 µM (A-B) or 4 µM (C-D). Samples were periodically collected from the treated cultures as indicated on the x-axis. These samples were frozen and later thawed simultaneously for mRNA quantification using QuantiGene Singleplex assays. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. N=3, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Comparison

    Jurkat cells were treated with siRNAs stabilized with 5’-VP and targeting PPIB at various concentrations as indicated in the color code (2 µM in orange, 1 µM in dark blue, 0.5 µM in light blue, A-B) or on the x-axis (C-D). The siRNAs were covalently conjugated to either a divalent myristic acid moiety (A and C) or cholesterol (B and D). Cells were either harvested 6 days post-treatment (B and D) or sampled periodically as indicated on the x-axis (A and C). Samples were frozen, later thawed, and mRNA was quantified using QuantiGene Singleplex assays. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-6, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: Jurkat cells were treated with siRNAs stabilized with 5’-VP and targeting PPIB at various concentrations as indicated in the color code (2 µM in orange, 1 µM in dark blue, 0.5 µM in light blue, A-B) or on the x-axis (C-D). The siRNAs were covalently conjugated to either a divalent myristic acid moiety (A and C) or cholesterol (B and D). Cells were either harvested 6 days post-treatment (B and D) or sampled periodically as indicated on the x-axis (A and C). Samples were frozen, later thawed, and mRNA was quantified using QuantiGene Singleplex assays. Data points from various time points and treatments were compared using two-way ANOVA with multiple comparison corrections. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N=3-6, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Comparison

    HeLa cells were initially transduced with a miR-155-expressing lentivirus and then transfected with a DualGlo plasmid containing the miR-155 target sequence cloned four times in tandem into the 3’ UTR of Rluc. The transfection was repeated once a week. The transduced and transfected cells were treated with a cholesterol-conjugated miR-155 inhibitor (A) and luminescence was measured using the DualGlo assay. The Rluc signal was normalized to the Fluc signal. Jurkat cells were also treated with the cholesterol-conjugated miR-155 inhibitor, and the miR-155 target, MYD88 mRNA, was quantified using the QuantiGene Singleplex assay on the days indicated on the x-axis (B). Data curves from various time points and treatments were compared using two-way ANOVA. N=3-10, mean ± SEM

    Journal: bioRxiv

    Article Title: Structure – silencing duration relationships in RNAi medicines in rapidly dividing cells

    doi: 10.1101/2024.09.09.612002

    Figure Lengend Snippet: HeLa cells were initially transduced with a miR-155-expressing lentivirus and then transfected with a DualGlo plasmid containing the miR-155 target sequence cloned four times in tandem into the 3’ UTR of Rluc. The transfection was repeated once a week. The transduced and transfected cells were treated with a cholesterol-conjugated miR-155 inhibitor (A) and luminescence was measured using the DualGlo assay. The Rluc signal was normalized to the Fluc signal. Jurkat cells were also treated with the cholesterol-conjugated miR-155 inhibitor, and the miR-155 target, MYD88 mRNA, was quantified using the QuantiGene Singleplex assay on the days indicated on the x-axis (B). Data curves from various time points and treatments were compared using two-way ANOVA. N=3-10, mean ± SEM

    Article Snippet: QGS assay (Invitrogen™QuantiGene™ Sample Processing Kit, cultured cells (QS0103, Life Technologies GmbH), Invitrogen™QuantiGene™ Singleplex Assay Kit (QS0016, Life Technologies GmbH)) was performed according to manufacturer’s protocol.

    Techniques: Transduction, Expressing, Transfection, Plasmid Preparation, Sequencing, Clone Assay, Singleplex Assay